CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating

Neutral
AI Analysis

Summary

RBC adjusted its price target for NewAmsterdam Pharma to $50 from $51 while maintaining an Outperform speculative risk rating.

Importance:2/10
Sentiment:
0.00
price_targetanalyst_ratingequity_research
Related Companies

Read the original article

Published by yahoo_finance on August 6, 2026 12:53 PM

Read Original